NVO Stock Up as Amycretin Shows Strong Weight Loss in Type 2 Diabetes
Shares of Novo Nordisk NVO were up 4.7% yesterday, after the company announced positive data from a phase II study evaluating its investigational pipeline candidate, amycretin, in people with type…